Title: A conserved membrane protein negatively regulates Mce1 complexes in mycobacteria

Authors: Yushu Chen[1], Yuchun Wang[1], Shu-Sin Chng[1,2]*

Affiliations:

[1] Department of Chemistry, National University of Singapore, Singapore 117543.

[2] Singapore Center for Environmental Life Sciences Engineering, National University of Singapore

(SCELSE-NUS), Singapore 117456.

* To whom correspondence should be addressed. Email: chmchngs@nus.edu.sg

Abstract

Tuberculosis continues to pose a serious threat to global health. *Mycobacterium tuberculosis*, the causative

agent of tuberculosis, is an intracellular pathogen that relies on various mechanisms to survive and persist

within the host. Among their many virulence factors, mycobacteria encode Mce systems. Some of these

systems are implicated in lipid uptake, but the molecular basis for Mce function(s) is poorly understood. To

gain insights into the composition and architecture of Mce systems, we characterized the putative Mce1

complex involved in fatty acid transport. We show that the Mce1 system in *Mycobacterium smegmatis*

comprises a canonical ATP-binding cassette transporter, associated with functionally redundant

heterohexameric assemblies of substrate-binding proteins. Furthermore, we establish that the conserved

membrane protein Mce1N negatively regulates Mce1 function via a unique mechanism involving blocking

transporter assembly. Our work offers molecular understanding of Mce complexes, sheds light on

mycobacterial lipid metabolism and its regulation, and informs future anti-mycobacterial strategies.

Introduction

Tuberculosis (TB) has been one of the top killers among single infectious diseases in humans, alone claiming 1.4 million lives out of 10.6 million new cases in 2021[1]. Apart from the active cases, it is estimated that one quarter of the world population have latent TB, which may progress into active infections[2]. TB is primarily caused by *Mycobacterium tuberculosis*, an organism known for its ability to adapt to the host environment and modulate the host immune system[3]. Its success as a pathogen can be owed to diverse virulence factors encoded in the genome of *M. tuberculosis*. In particular, many of these virulence factors promote host adaptation by contributing to the acquisition and catabolism of important nutrients, including metals, sugars and lipids[4].

mce operons were initially recognized as virulence factors in *M. tuberculosis*[5] and later found to be widespread throughout the *Mycobacterium* genus[6]. *M. tuberculosis* contains four *mce* operons, individually important determinants of virulence and collectively critical for pathogenesis[7–10]. *Mycobacterium smegmatis*, an environmental microorganism, contains six *mce* operons, while *Mycobacterium leprae*, the causative agent of leprosy, has only one such operon (*mce1*) in its highly degenerate genome[6]. In general, an *mce* operon consists of eight genes, two *yrbE* (e.g., *yrbE1A/B*) and six *mce* genes (e.g., *mce1A–F*), with different numbers of accessory genes[6] that may be required for function[11,12] (e.g., *mam1A–D* after the *mce1* operon). Furthermore, a gene encoding a transcriptional regulator (e.g., *mce1R*) can be found upstream of some *mce* operons[6,13,14] (Fig. 1a and Supplementary Fig. 1). The *mce1* and *mce4* operons have been implicated in fatty acid and cholesterol uptake, respectively[9,11,15]. Our understanding of how these operons facilitate lipid uptake is limited.

It is believed that *mce* operons encode ATP-binding cassette (ABC) transporters that are analogous to the MlaFEDB complex in Gram-negative bacteria[6,16], which is important for retrograde transport of phospholipids[17,18]. In MlaFEDB, MlaF, MlaE and MlaD represent the nucleotide-binding domains (NBDs), transmembrane domains (TMDs), and substrate-binding proteins (SBPs), respectively[19,20]. In Mce systems, YrbEA/Bs and MceA–Fs would form the corresponding TMDs and SBPs based on homology; here, MceG, a protein not encoded within *mce* operons, is thought to constitute the NBDs that energize all these putative transporters[21,22] (Fig. 1b). MlaD and MceA–F all contain a single mammalian cell entry (MCE) domain. Interestingly, MlaD and other MCE-domain proteins, such as PqiB and YebT/LetB, have been shown to

form homohexamers that provide a hydrophobic tunnel each, presumably for lipid substrate transport[19,20,23,24]. The fact that *mce* operons encode six Mce proteins MceA–F hints at the possible formation of heterohexameric MCE assemblies within each putative transporter. Despite similarities to MlaFEDB, however, there has been a lack of biochemical studies on mycobacterial Mce systems, and their exact compositions and overall architectures remain unknown.

Here, we biochemically characterized the putative Mce1 complex in *M. smegmatis*. We show that this system is important for fatty acid uptake, akin to the *M. tuberculosis* Mce1 complex[11,15]. We demonstrate that Mce1 is an ABC transporter comprising a core complex of YrbE1A/B-MceG, associated with a likely heterohexamer of Mce1A–F. We reveal that MSMEG_6540 is a functional homolog that can possibly replace Mce1A in the complex, and in fact, contributes more significantly to the fatty acid uptake function of Mce1. Furthermore, we identify MSMEG_0959, herein renamed to Mce1N, as a negative regulator of the Mce1 system; it prevents MceG from associating with the complex via competitive binding to YrbE1B, thereby modulating transport activity. Our work provides critical insights into the architecture, function and regulation of Mce systems in mycobacteria.

Results

Key proteins encoded in the *mce1* operon co-purify as a complex

To probe the composition of the putative Mce1 complex, we expressed His-tagged YrbE1A or YrbE1B in *M. smegmatis* using an integrative plasmid, and conducted affinity purification following cell lysis and detergent extraction from total membranes. This was done in a Δ*mce1R* strain, where the *mce1* operon is presumably up-regulated[13]. We found that His-tagged YrbE1B, but not YrbE1A, pulled down two distinct protein bands at ~45 and ~19 kDa (Fig. 1c). Tandem mass spectrometry (MS/MS) sequencing of the excised bands indicated that they were MceG (39.0 kDa) and a protein of unknown function, MSMEG_0959 (19.1 kDa), respectively. We did not observe additional bands corresponding to other expected members of the Mce1 complex, possibly due to low cellular levels, or instability of the complex *ex vivo*. To detect potential low abundance proteins specifically co-purified with His-tagged YrbE1B, we directly subjected entire gel lanes divided into two sections to MS/MS protein identification. Remarkably, this facilitated the detection of all other putative Mce1 components, including YrbE1A and Mce1A–F, similar to a recent report

identifying YrbE4A/B, Mce4A–F and MceG as components of the Mce4 complex[12]. Interestingly, a seventh

MCE-domain protein MSMEG_6540[6] was also co-purified with His$_6$-YrbE1B, while none of the putative

Mce-associated membrane proteins (Mam1A–D and OmamA/B[25]) or LucA[11] was identified. Our data

suggest that the Mce1 complex likely comprises the core ABC transporter YrbE1A/B-MceG associated

with a presumed heterohexamer of MCE-domain proteins.

MSMEG_6540 and Mce1A are redundant components of the Mce1 system

MSMEG_6540 shares 80% primary sequence identity with Mce1A, compared to less than 20% with

other MCE-domain proteins in the Mce1 complex and ~25% with MceA proteins in other putative *M.*

smegmatis Mce complexes (Supplementary Table 1). Another Mce1A paralog MSMEG_5818[6], which is

only 60% identical, was not co-purified with His-tagged YrbE1B (Fig. 1c). This suggests that

MSMEG_6540 could be a functional homolog of Mce1A. We also hypothesized that MSMEG_6540 and

Mce1A form heterohexamers with Mce1B–F in distinct complexes. To test these ideas, we examined the

effects of removing each MCE-domain protein on fatty acid uptake, a key function of the Mce1 complex[11,15].

Deletion of *yrbE1A/B* or *mceG*, both of which are expected to abolish Mce1 function, resulted in

significantly reduced [^{14}C]-palmitic acid uptake in cells (Fig. 2a and Supplementary Fig. 2). We established

that [^{14}C]-palmitic acid uptake was also reduced to the baseline, i.e., at levels of Δ*yrbE1A/B* cells, in

individual Δ*mce1B*, Δ*mce1C*, Δ*mce1D*, Δ*mce1E* or Δ*mce1F* mutants. The Δ*mce1C* and Δ*mce1D* strains

could be complemented by ectopic expression of the deleted gene alone (i.e., no polar effects) (Fig. 2b).

The Δ*mce1B*, Δ*mce1E* or Δ*mce1F* mutants could be fully complemented only when the deleted gene was

expressed together with downstream genes, but not when the latter alone was expressed (Fig. 2c–e).

Therefore, each of Mce1B–F should be present in all Mce1 complexes and required for fatty acid uptake

function.

Unexpectedly, removing Mce1A did not abolish, yet somehow gave increased [^{14}C]-palmitic acid

uptake (Fig. 2a). In contrast, the uptake was significantly less efficient in cells lacking *MSMEG_6540*, and

only further reduced to the baseline in the Δ*mce1A*Δ*6540* double mutant (Fig. 2a). We showed that

expressing *mce1A* in the double mutant increased palmitic acid uptake slightly, to levels similar to the

Δ*MSMEG_6540* strain, while expressing *MSMEG_6540* brought uptake to levels higher than wild type

(WT) cells, akin to the Δ*mce1A* strain (Fig. 2f). Our results indicate that Mce1A and MSMEG_6540 are

functionally redundant, with MSMEG_6540 being more efficient in mediating fatty acid uptake. In fact,

expressing Mce1A or MSMEG_6540 in WT cells decreased or increased palmitic acid uptake, respectively,

in a Mce1-dependent manner (Supplementary Fig. 3). We conclude that Mce1A and MSMEG_6540

compete to form distinct heterohexamers together with Mce1B–F, with the latter Mce1 complex playing a

more important role in fatty acid uptake in *M. smegmatis*.

YrbE1A/B-MceG constitute the core ABC transporter

We attempted but failed to over-express the *mce1* operon along with *mceG* in *E. coli*. Expression levels

of Mce1A–F were very low, which precluded purification of any stable Mce1 complex. Instead, we were

able to isolate the core ABC transporter when we co-expressed YrbE1A, His-tagged YrbE1B and MceG.

This complex eluted as a single peak on size exclusion chromatography (Fig. 3a); we showed that the

purified complex exhibits ATP hydrolytic activity (Fig. 3b), implying proper assembly of YrbE1A/B-MceG.

Interestingly, we found that His-tagged YrbE1B alone could pull down MceG when co-expressed in *E. coli*.

In contrast, His-tagged YrbE1A could only co-purify with MceG in the presence of YrbE1B, indicating that

the TMD-NBD interactions are mainly mediated through YrbE1B (Fig. 3c). Consistent with this idea, an

AlphaFold2 structural model of the YrbE1A/B-MceG complex[26–28], which resembles the homologous

MlaFE structure from Gram-negative bacteria (RMSD = 2.934 Å)[29], presented a smaller buried area

between MceG and YrbE1A (699 Å^2) compared to YrbE1B (837 Å^2) (Supplementary Fig. 4 and Table 2).

We conclude that the TMD and NBD proteins of the Mce1 system interact asymmetrically to form a stable

functional ABC transporter.

MSMEG_0959 is a negative regulator of Mce1

In addition to MceG, MSMEG_0959 was another protein abundantly co-purified with His-tagged

YrbE1B expressed in *M. smegmatis*. MSMEG_0959 is a putative conserved membrane protein with

unknown function; it contains two predicted transmembrane helices (TM1: W39–G59; TM2: L65–T90)

and a C-terminal cytoplasmic domain (S91–P178) (Supplementary Fig. 5a). We initially hypothesized that

it might function to stabilize the Mce1 complex, analogous to the role of the cytoplasmic protein MlaB in

the Gram-negative MlaFEDB complex[19]. To test this idea, we attempted to isolate a stable complex

containing YrbE1A/B, MceG and MSMEG_0959. To our surprise, when these four proteins were co-

expressed and purified from *E. coli*, only MSMEG_0959 was co-purified with His-tagged YrbE1B (Fig.

4a). We detected much less YrbE1A and essentially no MceG co-purified, suggesting that MSMEG_0959

may destabilize the Mce1 complex instead. In support of this notion, when MSMEG_0959 was over-

expressed in *M. smegmatis*, much less MceG was co-purified with His-tagged YrbE1B (Fig. 4c). We

conclude that MSMEG_0959 may disrupt YrbE1A/B-MceG interactions.

Since TMD-NBD interactions within the Mce1 complex is largely mediated through YrbE1B, we

presumed that MSMEG_0959 directly interacts with YrbE1B. Indeed, His-tagged YrbE1B alone, but not

YrbE1A, pulled down MSMEG_0959 when co-expressed in *E. coli*, consistent with affinity purification

results in *M. smegmatis* (Fig. 1c, Supplementary Fig. 6a and b). We generated an AlphaFold2 structural

model comprising YrbE1B and MSMEG_0959[26–28], predicting possible interactions between the

transmembrane domain of MSMEG_0959 and that of YrbE1B opposite its dimerization surface with

YrbE1A (Fig. 4d). To test the validity of this model, we introduced cysteine pairs across potential contact

sites in the transmembrane regions of the two proteins, and looked for disulfide bond formation when these

variants are expressed in *E. coli*. Five pairs of cysteines at the periplasmic side of the putative interface

enabled crosslinking between YrbE1B and MSMEG_0959 (Fig. 5), lending confidence to the predicted

interaction mode. The AlphaFold2 model revealed that an unstructured loop in the cytoplasmic domain of

MSMEG_0959 may contact a short helix of YrbE1B sitting at the membrane-water boundary. This helix

may be a determinant of the interaction between YrbE1B and MSMEG_0959 since the amino acid sequence

of this region is very different from that in YrbE1A (Supplementary Fig. 6c and d). Mutating part of this

helix (RLVAEIGMGT) to a flexible loop (GGSSG) did not affect the stability of the YrbE1A/B-MceG

complex; however, this mutation prevented co-purification of MSMEG_0959 with His-tagged YrbE1B

from *E. coli*, at the same time alleviating the destabilizing effect of MSMEG_0959 on YrbE1A/B-MceG

interactions (Fig. 4a). Notably, overlay of the models of YrbE1B-MSMEG_0959 and YrbE1A/B-MceG

highlighted substantial steric clashes between MceG and the cytoplasmic domain of MSMEG_0959 (Fig.

4d), indicating that their respective interactions with YrbE1B are likely competitive and mutually exclusive.

We also generated an MSMEG_0959 variant (MSMEG_0959$_{AGG3P}$) where the cytoplasmic loop that

appears to interact with YrbE1B is modified ([131]ALGELTG to PLPELTP) to impact overall conformation.

Intriguingly, this variant still interacts with YrbE1B but is no longer able to compete out MceG when co-

expressed in either *E. coli* (Fig. 4b) or *M. smegmatis* (Fig. 4c). Taken together, our results establish that

MSMEG_0959 specifically binds YrbE1B and prevents association of the NBD (MceG) to this ABC

transporter.

Our biochemical experiments suggest that MSMEG_0959 may be a negative regulator of the Mce1

complex. Consistent with this idea, MSMEG_0959 over-expression inhibited [^{14}C]-palmitic acid uptake in

WT cells, but not residual uptake observed in Δ*yrbE1A/B* cells (Fig. 4e). In contrast, over-expression of

MSMEG_0959$_{AGG3P}$ did not inhibit [^{14}C]-palmitic acid uptake at all (Fig. 4e), in line with its inability to

displace MceG (Fig. 4c). Furthermore, we found that over-expression of Rv0513, the *M. tuberculosis*

homolog of MSMEG_0959, reduced the amount of MceG associated with YrbE1B (Fig. 4c) in *M.*

smegmatis, and slowed down [^{14}C]-palmitic acid uptake (Fig. 4e). We therefore conclude that

MSMEG_0959/Rv0513, herein renamed to Mce1N (Mce1 negative regulator), inhibits the fatty acid uptake

function of the Mce1 transporter(s) via a conserved mechanism that involves prevention of YrbE1B-MceG

interaction.

Discussion

In this study, we set out to characterize the Mce1 complex in *M. smegmatis*. We have shown that the

Mce1 complexes likely comprise the core inner membrane ABC transporter YrbE1A/B-MceG, associated

with heterohexamers composed of Mce1A–F or MSMEG_6540/Mce1B–F. We have demonstrated that

MSMEG_6540 is functionally redundant with Mce1A, and indeed more important in the newly

characterized fatty acid uptake function of Mce1 in *M. smegmatis*. Furthermore, we have discovered a

negative regulator of the Mce1 complex, Mce1N, which physically hinders the dominant TMD-NBD

interaction (i.e., YrbE1B-MceG) in the ABC transporter. Our work provides novel insights into the

architecture and regulation of mycobacterial Mce complexes.

Based on analogy to other MCE-domain proteins, such as MlaD, PqiB[20] and YebT/LetB[23,24] involved

in lipid transport in Gram-negative bacteria (Supplementary Fig. 7a), Mce1A–F and

MSMEG_6540/Mce1B–F likely form hexamers. Each of these Mce proteins contains a single MCE domain

(like MlaD) and an extended helical domain (like PqiB), followed by the presence of an additional C-terminal domain of varied sizes. According to AlphaFold2 prediction[26,27,30], Mce1A or MSMEG_6540 can indeed form a heterohexamer with Mce1B–F (Supplementary Fig. 7b). In contrast, a homohexameric model of Mce1A alone could not be generated, agreeing with an earlier observation that the MCE domain of *M. tuberculosis* Mce1A predominantly forms monomers in solution[31]. In the AlphaFold2 model, the heterohexamer adopts an architecture that comprises a hexameric MCE ring connected to a tube formed by a bundle of helical domains; the C-terminal domains of the six Mce proteins organize to form a possible substrate entry point at the very tip (Supplementary Fig. 7b). A continuous hydrophobic tunnel runs through the entire assembly that likely extends across the periplasm to contact the mycobacterial outer membrane (Fig. 6, Supplementary Fig. 7b and c), consistent with its function in lipid uptake. This predicted model resembles the recently solved cryo-electron microscopy (EM) structure of the Mce1 complex remarkably well[32]. Interestingly, *M. smegmatis* possesses MSMEG_6540 as a functional homolog of Mce1A, highlighting the presence of two variants of Mce1 complexes[6], containing Mce1B–F and either Mce1A or MSMEG_6540 (Fig. 6). In support of this idea, removing any other MCE-domain protein in Mce1, but not Mce1A or MSMEG_6540 alone, completely abolishes function in fatty acid uptake (Fig. 2). Differences between the primary sequences of Mce1A and MSMEG_6540 lie mainly in the extreme C-terminal domain, with differing residues primarily mapped to the substrate entry point in the AlphaFold2 models (Supplementary Fig. 7d). We propose that Mce1 complexes containing either Mce1A or MSMEG_6540 may have distinct substrate specificities, perhaps advantageous for an environmental microorganism like *M. smegmatis*.

Despite the fact that there are known ABC transporters with heterodimeric TMDs, it has not been appreciated that such asymmetry can give rise to major differences in affinity between each TMD and NBD pair—in the case of the Mce1 transporter, the NBD dimer may be predominantly recruited by YrbE1B (Fig. 3c). This might be applicable to other ABC transporters with heterodimeric TMDs since TMD-NBD interfaces of different areas were also observed within some of them (Supplementary Table 2). That TMD-NBD association in the Mce1 transporter relies on the YrbE1B-MceG interaction offers a compelling reason why the negative regulator Mce1N also selectively binds YrbE1B (Fig. 1c, Supplementary Fig. 6a and b). Based on our modeling and biochemical data (Fig. 4a and d), the cytoplasmic domain of Mce1N likely

interacts with YrbE1B extensively at a short helix between the latter's N-terminal amphipathic interface helix and TM1. This short helix is nominally a part of TM1 but is presented at an angle due to a kink introduced by a flexible loop within TM1. Remarkably, this structural feature may be exclusively conserved across YrbEBs, but not YrbEAs (Supplementary Fig. 8). This raises an interesting possibility that beyond the most conserved Mce1 complex, Mce1N may also regulate additional Mce systems by binding to the corresponding YrbEB, perhaps providing a way to redistribute MceG among all Mce systems.

The discovery of a negative regulator that competes with the NBD for binding to the TMDs may be unique to Mce complexes, as known regulatory mechanisms for ABC transporters typically involve modulation of ATPase activity instead of removing the NBD from the complex[19,33–37]. How and when the Mce1 complex is modulated would directly depend on the levels of Mce1N (Fig. 6), which is highly conserved across the *Mycobacterium* genus (present in both fast- and slow-growing, pathogenic and non-pathogenic species). We note that *mce1N* may be in an operon together with four upstream essential genes involved in porphyrin biosynthesis (*hemACDB*). Porphyrin biosynthesis has been reported to increase, suggesting possible up-regulation of Mce1N (MSMEG_0959), when *M. smegmatis* cells enter dormancy[38]. In this situation, negative regulation by Mce1N might be a strategy that cells use to inhibit some Mce complexes to conserve ATP. Alternatively, Mce1N levels may correlate with the need for lipid uptake. Outside the host, where fatty acid substrates may be scarce, it might be preferable for mycobacterial cells to keep the Mce1 system in a routinely OFF state and avoid futile ATP hydrolysis. During infection, however, cells may require a fully active Mce1 complex to utilize host fatty acids. We do not yet know of any environment-dependent regulation of Mce1N. However, it is noteworthy that in *M. leprae*, which possesses Mce1 as the only Mce system[6], Mce1N (ML2418) lacks the C-terminal cytoplasmic domain (Supplementary Fig. 5b) and is likely non-functional. Combined with the fact that *mce1R*, the gene encoding the transcriptional repressor of the *mce1* operon (Supplementary Fig. 1), is absent in *M. leprae*, the pathogen may have lost its ability to down-regulate the Mce1 system, which can facilitate constitutive fatty acid uptake during its obligate parasitic life cycle.

We have uncovered a new regulatory mechanism for Mce1 (Fig. 6), and potentially other Mce systems, which may have implications for how mycobacterial cells coordinate lipid uptake processes. Despite the presence of a transcriptional regulator for some *mce* operons (Supplementary Fig. 1), all Mce transporters

apparently share the same ATPase MceG[22]. This indicates that mycobacterial cells have the ability to

modulate the levels of each complex, yet adjust their activities simultaneously. In the same vein, we

speculate that Mce1N could also be a shared negative regulator to counter MceG binding/activation, and

primarily functions to deactivate all Mce complexes simultaneously. Whether Mce1N has preferences for

specific Mce systems remains to be examined. Nevertheless, it likely contributes significantly to the overall

regulation towards maintaining a balanced metabolic flux of different lipid substrates required for

mycobacterial survival[11,39], which may involve other yet-to-be-identified uptake transporters beyond Mce

systems[40].

Methods

Plasmid construction

Plasmids used in this study were constructed by traditional ligation or Gibson assembly, with mutations

introduced by site-directed mutagensis if applicable. Primers used for constructing the plasmids are listed

in Supplementary Table 6. Backbone plasmids were digested with relevant restriction enzymes (New

England Biolabs). Desired DNA fragments to be inserted were amplified by PCR. For traditional ligation,

the insert was digested with the same restriction enzymes as the backbone and ligated with the backbone

using T4 DNA ligase (New England Biolabs). For Gibson assembly, desired DNA fragments were inserted

into linearized backbones using ClonExpress Ultra One Step Cloning Kit (Vazyme). For site-directed

mutagenesis, mutations were introduced to the plasmid using PCR with the original plasmid as the template

and primers containing expected changes.

Construction of *M*. *smegmatis* knock-out strains

M. smegmatis strains used in this study are listed in Supplementary Table 3. The knockout strains were

constructed by two-step homologous recombination as reported previously[41]. Briefly, a suicide plasmid

pYUB854 with no replication origin and a *hygR* cassette was used as the backbone for insertion of two

flanking regions of the target gene side by side, and a *lacZ-sacB* cassette for blue-white screening and

negative selection on sucrose. The plasmid was electroporated at 2250 V using Eporator (Eppendorf) into

M. *smegmatis* mc^{2}155 electrocompetent cells, which were subsequently plated on LB plates containing 50

μg/mL hygromycin and 20 μg/mL 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal). The plate

was incubated at 37 °C for 5–7 days to allow the growth of first cross-over cells (those forming blue colonies

on the plate). Cells harboring the first cross-over at the targeted site were grown in Middlebrook 7H9 broth

containing 0.5% glycerol and 0.05% tyloxapol and spread onto LB plates containing 20 μg/mL X-gal and

5% sucrose. The plate was again incubated at 37 °C for 4 days to allow the growth of second cross-overs

(those forming whitish-yellow colonies on the plate). Correct gene deletion mutants were screened by PCR

and Sanger sequencing (Bio Basic Asia Pacific, Singapore) among the second cross-overs.

Pull-down assay in *M. smegmatis*

Plasmids used in this study for protein expression in *M. smegmatis* are listed in Supplementary Table

4. pJEB402 or pMV306hsp vectors carrying genes of interest were transformed into *M. smegmatis* cells by

electroporation. The cells were grown in 750 mL tryptic soy broth (TSB) supplemented with 0.05% Tween

80 to stationary phase (OD_{600} ~5) and harvested by centrifugation at 4,800 xg for 10 min. Harvested cells

were resuspended in cold 20 mL TBS (Tris-buffered saline, 20 mM Tris-HCl pH 8.0, 150 mM NaCl)

containing 100 μg/mL lysozyme, 100 μM phenylmethylsulfonyl fluoride, and 50 μg/mL DNase I, and lysed

by two passages through a French Press (GlenMills) at 18,000 psi. The resulting suspension was centrifuged

at 4,800 xg for 4 min to remove unbroken cells. The supernatant containing the cell lysate was subjected to

centrifugation at 95,000 xg for 45 min. The pelleted membrane was resuspended in 5 mL extraction buffer

(TBS pH 8.0 containing 5 mM $MgCl_2$, 10% glycerol, 5 mM imidazole, and 1% n-dodecyl-β-D-maltoside

(DDM)) and extracted on ice with gentle shaking for 2 h. The suspension was subjected to a second round

of centrifugation at 89,000 xg for 45 min. The supernatant was loaded onto 100 μL TALON metal affinity

resin (Takara Bio) pre-equilibrated with TBS pH 8.0 containing 10 mM imidazole. The mixture was allowed

to drain by gravity and the filtrate was loaded back to the column and drained again. The resin was washed

with 500 μL washing buffer (20 mM Tris-HCl pH 8.0, 300 mM NaCl, 5 mM $MgCl_2$, 10% glycerol, 8 mM

imidazole, and 0.05% DDM) for ten times and subsequently eluted with 100 μL elution buffer (TBS pH 8.0

containing 5 mM $MgCl_2$, 10% glycerol, 200 mM imidazole, and 0.05% DDM) for four times. The eluate

was concentrated using an Amicon Ultra 10 kDa centrifugal filter (MilliporeSigma) and kept for further

SDS-PAGE analysis. Protein gel sections and bands to be identified were sent to Taplin Biological Mass

 Spectrometry Facility, Harvard Medical School (Boston, MA) for capillary LC-MS/MS analysis.

Protein purification from *E. coli*

Plasmids used in this study for protein expression in *E. coli* are listed in Supplementary Table 5. *E. coli* BL21(λDE3) cells were used as the host strain. Cells were grown to $OD_{600} = 0.6$ in 1.5 L LB broth, before 1 mM IPTG was added to induce expression of the proteins for 2 h. The cells were harvest by centrifugation at 4,800 xg for 10 min. Harvested cells were resuspended in cold 20 mL TBS (Tris-buffered saline, 20 mM Tris-HCl pH 8.0, 150 mM NaCl) containing 100 µg/mL lysozyme, 100 µM phenylmethylsulfonyl fluoride, and 50 µg/mL DNase I, and lysed by two passages through a French Press at 18,000 psi. The resulting suspension was centrifuged at 4,800 xg for 4 min to remove unbroken cells. The supernatant containing the cell lysate was subjected to centrifugation at 95,000 xg for 45 min. The pelleted membrane was resuspended in the 5 mL extraction buffer (TBS pH 8.0 containing 5 mM $MgCl_2$, 10% glycerol, 5 mM imidazole, and 1% DDM) and extracted on ice with gentle shaking for 2 h. The suspension was subjected to a second round of centrifugation at 89,000 xg for 45 min. The supernatant was loaded onto TALON metal affinity resin (Takara Bio) pre-equilibrated with TBS pH 8.0 containing 10 mM imidazole. The mixture was allowed to drain by gravity and the filtrate was loaded back to the column and drained again. The resin was washed 10 times with the washing buffer (20 mM Tris-HCl pH 8.0, 300 mM NaCl, 5 mM $MgCl_2$, 10% glycerol, 8 mM imidazole, and 0.05% DDM) and subsequently eluted with the elution buffer (TBS pH 8.0 containing 5 mM $MgCl_2$, 10% glycerol, 200 mM imidazole, and 0.05% DDM). The eluate was concentrated using an Amicon Ultra 10 kDa centrifugal filter (MilliporeSigma) and subjected to SDS-PAGE analysis. YrbE1A/B-MceG and YrbE1A/B-MceG$_{K43A}$ were further purified and analyzed by SEC (AKTA, GE Healthcare) at 4 ⁰C on a pre-packed Superdex Increase 200 10/300 GL column (Cytiva). TBS pH 8.0 containing 5 mM $MgCl_2$, 10% glycerol, and 0.05% DDM was used as the eluent. Fractions corresponding to the peaks of our interest were concentrated and subjected to SDS-PAGE analysis.

SDS-PAGE and Western Blotting

Protein samples were mixed with Laemmli buffer and analyzed by Tris-glycine SDS-PAGE. The gel was visualized by InstantBlue Coomassie Blue Stain (Abcam) or subjected to Western blotting. For the

latter, the proteins on the gel were transferred to a polyvinylidene fluoride membrane using a Transblot SD semi-dry transfer system (BioRad) at 25V for 30 min. The membrane was blocked in 1x casein blocking buffer for at least 1 h. For detection of His-tagged proteins, a conjugate of mouse monoclonal penta-His antibody and horseradish peroxidase (Qiagen) was used. For detection of FLAG-tagged proteins, a conjugate of mouse monoclonal FLAG-antibody and horseradish peroxidase (MilliporeSigma) was used. To visualize the blots, Luminata Forte Western HRP Substrate (MilliporeSigma) was applied to the membrane.

Disulfide bond analysis

His$_6$-YrbE1B and MSMEG_0959-FLAG were over-expressed in *E. coli* BL21(λDE3) cells harboring pET28b*his$_6$-yrbE1B* and pCDFduet*MSMEG_0959-FLAG*, with site-specific cysteine substitutions. The cells were grown to OD_{600} = 0.6 in LB broth, before 1 mM IPTG was added to induce expression of the proteins for 2 h. The cells were harvest by centrifugation at 4,000 xg for 3 min. The pellets were resuspended in 2x Laemmeli buffer with (for reducing conditions) or without (for non-reducing conditions) 10% β-mecaptoethanol. The samples were centrifuged at 21,000 xg for 10 min before being subjected to SDS-PAGE and immunoblot analyses.

Determination of cell growth in different media

M. smegmatis cells were grown in Middlebrook 7H9 broth containing 0.5% glycerol and 0.05% tyloxapol to an OD_{600} around 2. The cells were subcultured into the same 7H9 medium or into Sauton's medium (0.5 g/L K$_2$HPO$_4$, 0.25 g/L MgSO$_4$, 2 g/L citric acid, 0.4 g/L L-asparagine, 0.05 g/L ferric ammonium citrate, 5 g/L fatty acid-free bovine serum albumin, 0.05% tyloxapol, pH 7.0) containing palmitic acid as the sole carbon source. The starting OD_{600} for the subculture was 0.001 for the 7H9 medium and 0.0001 for the Sauton's medium. To prepare the Sauton's medium, palmitic acid was dissolved in 0.1 M NaOH, heated to 80 ⁰C and added into the medium with constant stirring to a final concentration of 300 μM. The cultures were incubated at 37 ⁰C with 200 rpm shaking. Growth of the cells were monitored at specified time points using a UV-Vis spectrophotometer at 600 nm.

Palmitic acid uptake assay

The palmitic acid uptake assay was adapted from the one used in ref. [11]. *M. smegmatis* cells were grown in the Middlebrook 7H9-glycerol-tyloxapol medium until the stationary phase and sub-cultured into Sauton's medium with palmitate as the carbon source or TSB for cells over-expressing Mce1Ns. Stationary-phase cells (OD_{600} ~0.4 for cells grown in Sauton and ~5 for those in TSB) were pelleted by centrifugation at 3,000 xg for 4 min and resuspended in 1x phosphate-buffered saline (PBS) supplemented with 0.05% Triton X-100 and 0.1% fatty acid-free bovine serum albumin (BSA) yielding a final OD_{600} of 0.8. [^{14}C]-palmitic acid (Perkin Elmer) was added to a final activity concentration of 0.2 µCi/mL. The cells were incubated at 37 °C with 200 rpm shaking. Cells were harvested at different time points (5, 15, 30, 45 min) by centrifugation at 5,000 xg for 1 min from 300 µL suspension and washed once with ice-cold PBS containing Triton X-100 and BSA. The cells were finally resuspended in the same buffer and aliquoted into three plastic scintillation vials for counting using a MicroBeta2 microplate counter (Perkin Elmer).

Enzyme-coupled ATPase assay

ATP hydrolytic activity was measured using an NADH-coupled assay[42] adapted for plate readers[43], as previously described[19]. Each 50 µL reaction is made up of 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM $MgCl_2$,10% glycerol, 0.05% DDM, 200 mM NADH (MilliporeSigma), 20 U/mL lactic dehydrogenase (MilliporeSigma), 100 U/mL pyruvate kinase (MilliporeSigma), 0.5 mM phosphoenolpyruvate (MilliporeSigma) and various ATP (MilliporeSigma) concentrations. Protein complexes were added to a final concentration of 0.1 µM. Fluorescence emission at 340 nm from the reaction mixture was monitored at 37°C with 15 s intervals using a Biotek Synergy H1 microplate reader equipped with Biotek Gen5 software (Agilent). A linear fit was performed for the measured fluorescence within 10 min reaction time to obtain the rate of decrease in NADH fluorescence, which was converted to ATP hydrolysis rates using a standard curve obtained with known ADP concentrations. The assay for each sample was performed in technical triplicates and the data were fit to the built-in Hill equation in OriginPro 2018b.

Bioinformatic and structural analyses

Topological prediction for MSMEG_0959 was done using the CCTOP server (http://cctop.ttk.hu/).

Sequence alignment of proteins was done using pairwise (EMBOSS needle) or multiple sequence alignment (Clustal Omega) tools provided by EMBL-EBI (https://www.ebi.ac.uk/services). Structural prediction for YrbE1A/B-MceG, YrbEA/Bs-MSMEG_0959 was done using ColabFold[28] on the Colaboratory server (Google). Prediction for Mce hexamers was done using the AlphaFold multimer tool on the COSMIC[2] platform[26,30]. For both predictions, no template information was used and Amber was used for relaxing the predicted models. Other settings were kept as default. Visualization of structures and overlay of structural models were performed using PyMOL 2.3.0. Interface analysis was performed using ChimeraX 1.4.

References

1. World Health Organization. Global Tuberculosis Report 2022. https://www.who.int/publications/i/item/9789240061729 (2022).

2. Houben, R. M. & Dodd, P. J. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. *PLoS Med*. **13**, e1002152 (2016).

3. Chai, Q., Zhang, Y. & Liu, C. H. *Mycobacterium tuberculosis*: an adaptable pathogen associated with multiple human diseases. *Front. Cell. Infect. Microbiol*. **8**, 158 (2018).

4. Forrellad, M. A. et al. Virulence factors of the *Mycobacterium tuberculosis* complex. *Virulence* **4**, 3-66 (2013).

5. Klepp, L. I., García, J. S. y & Bigi, F. Mycobacterial MCE proteins as transporters that control lipid homeostasis of the cell wall. *Tuberculosis (Edinb)* **132**, 102162 (2022).

6. Casali, N. & Riley, L. W. A phylogenomic analysis of the *Actinomycetales mce* operons. *BMC Genomics* **8**, 60 (2007).

7. Shimono, N. et al. Hypervirulent mutant of *Mycobacterium tuberculosis* resulting from disruption of the *mce1* operon. *Proc. Natl. Acad. Sci. U. S. A*. **100**, 15918-15923 (2003).

8. Gioffré, A. et al. Mutation in *mce* operons attenuates *Mycobacterium tuberculosis* virulence. *Microbes Infect*. **7**, 325-334 (2005).

9. Pandey, A. K. & Sassetti, C. M. Mycobacterial persistence requires the utilization of host cholesterol. *Proc. Natl. Acad. Sci. U. S. A*. **105**, 4376-4380 (2008).

10. Senaratne, R. H. et al. *Mycobacterium tuberculosis* strains disrupted in *mce3* and *mce4* operons are

attenuated in mice. *J. Med. Microbiol.* **57**, 164-170 (2008).

11. Nazarova, E. V et al. Rv3723/LucA coordinates fatty acid and cholesterol uptake in *Mycobacterium*

tuberculosis. eLife **6** (2017).

12. Rank, L., Herring, L. E. & Braunstein, M. Evidence for the mycobacterial Mce4 transporter being a

multiprotein complex. *J. Bacteriol.* **203**, e00685-00620 (2021).

13. Casali, N., White, A. M. & Riley, L. W. Regulation of the *Mycobacterium tuberculosis mce1* operon. *J.*

Bacteriol. **188**, 441-449 (2006).

14. Santangelo, M. P. et al. Study of the role of Mce3R on the transcription of *mce* genes of *Mycobacterium*

tuberculosis. BMC Microbiol. **8**, 38 (2008).

15. Forrellad, M. A. et al. Role of the Mce1 transporter in the lipid homeostasis of *Mycobacterium*

tuberculosis. Tuberculosis (Edinb) **94**, 170-177 (2014).

16. Malinverni, J. C. & Silhavy, T. J. An ABC transport system that maintains lipid asymmetry in the Gram-

negative outer membrane. *Proc. Natl. Acad. Sci. U. S. A.* **106**, 8009-8014 (2009).

17. Tang, X. et al. Structural insights into outer membrane asymmetry maintenance in Gram-negative

bacteria by MlaFEDB. *Nat. Struct. Mol. Biol.* **28**, 81-91 (2021).

18. Low, W.-Y., Thong, S. & Chng, S.-S. ATP disrupts lipid-binding equilibrium to drive retrograde

transport critical for bacterial outer membrane asymmetry. *Proc. Natl. Acad. Sci. U. S. A.* **118** (2021).

19. Thong, S. et al. Defining key roles for auxiliary proteins in an ABC transporter that maintains bacterial

outer membrane lipid asymmetry. *eLife* **5** (2016).

20. Ekiert, D. C. et al. Architectures of Lipid Transport Systems for the Bacterial Outer Membrane. *Cell*

169, 273-285 e217 (2017).

21. Joshi, S. M. et al. Characterization of mycobacterial virulence genes through genetic interaction

mapping. *Proc Natl Acad Sci U S A* **103**, 11760-11765 (2006).

22. Garcia-Fernández, J., Papavinasasundaram, K., Galán, B., Sassetti, C. M. & García, J. L. Unravelling

the pleiotropic role of the MceG ATPase in *Mycobacterium smegmatis. Environ. Microbiol.* **19**, 2564-

2576 (2017).

23. Liu, C., Ma, J., Wang, J., Wang, H. & Zhang, L. Cryo-EM structure of a bacterial lipid transporter YebT.

J. Mol. Biol. **432**, 1008-1019 (2020).

24. Isom, G. L. et al. LetB structure reveals a tunnel for lipid transport across the bacterial envelope. *Cell*
181, 653-664 (2020).

25. Perkowski, E. F. et al. An orphaned Mce‑associated membrane protein of *Mycobacterium tuberculosis*
is a virulence factor that stabilizes Mce transporters. *Mol. Microbiol.* **100**, 90-107 (2016).

26. Evans, R. et al. Protein complex prediction with AlphaFold-Multimer. Preprint at
https://www.biorxiv.org/content/10.1101/2021.10.04.463034v2 (2022).

27. Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. *Nature* **596**, 583-589
(2021).

28. Mirdita, M. et al. ColabFold: making protein folding accessible to all. *Nat. Methods* **19**, 679-682 (2022).

29. Zhou, C. et al. Structural insight into phospholipid transport by the MlaFEBD complex from *P.*
aeruginosa. *J. Mol. Biol.* **433**, 166986 (2021).

30. Cianfrocco, M. A., Wong, M., Youn, C., Wagner, R. & Leschziner, A. E. COSMIC²: A science gateway
for cryo-electron microscopy structure determination. *Proceedings of the Practice and Experience in*
Advanced Research Computing 2017 on Sustainability, *Success and Impact* 1-5 (2017).

31. Asthana, P. et al. Structural insights into the substrate-binding proteins Mce1A and Mce4A from
Mycobacterium tuberculosis. *IUCrJ* **8**, 757-774 (2021).

32. Chen, J. *et al*. Structure of an endogenous mycobacterial MCE lipid transporter. Preprint at
https://www.biorxiv.org/content/10.1101/2022.12.08.519548v2 (2022).

33. Crawford, R. R., Potukuchi, P. K., Schuetz, E. G. & Schuetz, J. D., Beyond competitive inhibition:
regulation of ABC transporters by kinases and protein-protein interactions as potential mechanisms of
drug-drug interactions. *Drug Metab. Dispos.* **46**, 567-580 (2018).

34. Kadaba, N. S., Kaiser, J. T., Johnson, E., Lee, A. & Rees, D. C. The high-affinity *E. coli* methionine
ABC transporter: structure and allosteric regulation. *Science* **321**, 250-253 (2008).

35. Gerber, S., Comellas-Bigler, M., Goetz, B. A. & Locher, K. P. Structural basis of trans-inhibition in a
molybdate/tungstate ABC transporter. *Science* **321**, 246-250.

36. Chen, S., Oldham, M. L., Davidson, A. L. & Chen, J. Carbon catabolite repression of the maltose
transporter revealed by X-ray crystallography. *Nature* **499**, 364-368 (2013).

37. Ko, S. B. et al. Gating of CFTR by the STAS domain of SLC26 transporters. *Nat. Cell. Biol.* **6**, 343-

350 (2004).

38. Nikitushkin, V. D. et al. The main pigment of the dormant *Mycobacterium smegmatis* is porphyrin.

FEMS Microbiol. Lett. **363** (2016).

39. Lee, W., VanderVen, B. C., Fahey, R. J. & Russell, D. G. Intracellular *Mycobacterium tuberculosis*

exploits host-derived fatty acids to limit metabolic stress. *J. Biol. Chem.* **288**, 6788-6800 (2013).

40. Martin, A. & J. Daniel. The ABC transporter Rv1272c of *Mycobacterium tuberculosis* enhances the

import of long-chain fatty acids in *Escherichia coli. Biochem. Biophys. Res. Commun.* **496**, 667-672

(2018).

41. Parish, T. & Stoker, N. G. Use of a flexible cassette method to generate a double unmarked

Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement. *Microbiology* **146**, 1969-1975

(2000).

42. Nørby, J. G. Coupled assay of Na^+, K^+-ATPase activity. *Methods Enzymol.* **156**, 116–119 (1988).

43. Kiianitsa, K., Solinger, J. A. & Heyer, W.-D. NADH-coupled microplate photometric assay for kinetic

studies of ATP-hydrolyzing enzymes with low and high specific activities. *Anal. Biochem.* **321**, 266-

271 (2003).

Data availability

All data are available in the main text or supplementary materials of this manuscript.

Acknowledgements

We thank Jia Fu Erh and Wei Shen Ho (National University of Singapore) for constructing plasmids and early affinity purification attempts. We are grateful to Beijing Genomics Institute (BGI) Research for providing DNA synthesis and assembly support. We thank Ross Tomaino (Taplin MS facility, Harvard Medical School) for help with protein identification. This work was supported by Singapore Ministry of Education Academic Research Fund Tier 2 grants MOE2019-T2-1-128 and MOE000116 (S.-S.C).

Author contributions

Y.C. and S.-S.C. conceptualized the study, designed the experiments, analyzed the data, and wrote the manuscript. Y.C. performed the experimental studies. Y.W. performed the disulfide crosslinking experiment. S.-S.C. supervised the study.

Competing interests

The authors declare that they have no competing interests.

Figure 1. Affinity purification with His$_6$-YrbE1B defines the composition of Mce1 complexes. a A

schematic representation of the *mce1* genetic loci in *M. smegmatis*. Each straight arrow represents an

individual gene. Lengths of the arrows are scaled to the lengths of the genes. The gene encoding a putative

transcriptional regulator of the *mce1* operon is colored in *yellow*. A gene encoding a putative acyl-CoA

synthase is colored in white. *yrbE* genes are colored in *blue*, *mce* genes *dark green*, *mam* genes *light green*,

and unrelated genes *grey*. The promoter position of the *mce1* operon is annotated with a turning arrow in

purple. **b** A basic model of the putative Mce1 complex based on current knowledge. SBP (Mce1A–F),

substrate-binding protein; TMD (YrbE1A/B), transmembrane domain; NBD (MceG), nucleotide-binding

domain; IM, inner membrane. **c** SDS-PAGE and α-His immunoblot analyses of proteins affinity-purified

from *M. smegmatis* Δ*mce1R* cells expressing His-tagged YrbE1A (p*his-yrbE1A*) or YrbE1B (p*his-yrbE1B)*.

pMV306hsp was used as the empty vector control. For protein identification from gel bands, the top three

proteins detected in the p*his-yrbE1B* lane are listed. For protein identification from gel sections (blue: 35–

90 kDa, green: 18–35 kDa), proteins with more than ten total peptides detected and significantly enriched

in the p*his-yrbE1B* lane are listed. CBB, Coomassie brilliant blue; MS, mass spectrometry.

Figure 2. MSMEG_6540 and Mce1A are redundant components that likely form heterohexamers

with Mce1B–F in Mce1 complexes. a–f [^{14}C]-palmitic acid uptake profiles and rates of indicated *M.*

smegmatis strains. Each uptake profile (*left*) shows accumulated radioactivity counts in cells over time, and

is representative of at least three independent experiments. Each data point (mean ± standard deviation)

represents results from three *technical* replicates. CPM, count per minute. Uptake rates (*right*) are

quantified based on [^{14}C]-palmitic acid levels after 30 min incubation. The uptake of individual strains is

normalized to that of wild type (WT) cells or WT cells harboring the empty vector (WT EV). Mean ±

standard deviation of three *biological* replicates is shown for each group. Welch's t-test: NS, not significant;

* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$. In **b**–**f**, different strains in **a** are complemented via expression of

indicated genes from a plasmid. *MSMEG_6540* and *mce1A–F* genes are annotated as *6540* and *1A–F*

respectively. EV, empty vector (pJEB402).

Figure 3. YrbE1A/B-MceG form a stable asymmetric complex with ATPase activity. a Size exclusion chromatographic profile of the purified complex comprising YrbE1A, His$_6$-YrbE1B and MceG. SDS-PAGE analysis of the peak corresponding to the complex (black arrowhead) is shown. b Enzyme-coupled ATPase assay of 0.1 μM YrbE1A/B-MceG and YrbE1A/B-MceG$_{K43A}$ in detergent micelles at 37 °C. Average ATP hydrolysis rates from three technical triplicates were plotted against ATP concentrations, and fitted to an expanded Michaelis-Menten equation that includes a term for Hill coefficient (n). YrbE1A/B-MceG: K$_m$ = 284 ± 311μM, k_{cat} = 0.184 ± 0.125 μM ATP s^{-1}/μM complex, n = 1.28 ± 0.57. The data for the mutant failed to fit to the equation with significant confidence. Each data point is shown as mean ± standard deviation. c SDS-PAGE and α-His/FLAG immunoblot analyses of proteins affinity-purified from *E. coli* cells over-expressing FLAG-tagged MceG together with either His$_6$-YrbE1A (H1A) with/without YrbE1B (1B) or His$_6$-YrbE1B (H1B) with/without YrbE1A (1A). CBB, Coomassie brilliant blue.

Figure 4. MSMEG_0959 negatively regulates the Mce1 transporter. a SDS-PAGE and α-His/FLAG immunoblot analyses of proteins affinity-purified from *E. coli* cells over-expressing YrbE1A, MceG, and either wild-type His$_6$-YrbE1B (WT) or the helix-to-loop mutant His$_6$-YrbE1B (GGSSG), in the presence (+) or absence (-) of MSMEG_0959-FLAG. **b** SDS-PAGE and α-His/FLAG immunoblot analyses of proteins affinity-purified from *E. coli* cells over-expressing YrbE1A, FLAG-tagged MceG, His-tagged YrbE1B together with FLAG-tagged wild type MSMEG_0959 (WT) or the loop-rigidified mutant (AGG3P). **c** SDS-PAGE and α-His/FLAG immunoblot analyses of proteins affinity-purified from *M. smegmatis* cells over-expressing His$_6$-YrbE1B as the bait protein together with MSMEG_0959, the loop-rigidified mutant (0959$_{AGG3P}$) or Rv0513 (Mce1N from *M. tuberculosis*). **d** An overlay of AlphaFold2 models of YrbE1B (*pink*)-MceG (*orange* surface) and YrbE1B-MSMEG_0959 (*cyan*). The helix-to-loop

mutation of YrbE1B located on the putative short helix at the YrbE1B-MSMEG_0959 interface is

highlighted in *red*. The rigidified loop on the MSMEG_0959$_{AGG3P}$ mutant is highlighted in *blue* (with an

arrowhead). The steric clash between MceG and MSMEG_0959 is indicated by a *red* arrow. Dashed lines

represent arbitrary membrane boundaries based on hydrophobicity of the transmembrane regions. **e** [^{14}C]-

palmitic acid uptake profiles and rates of indicated *M. smegmatis* strains over-expressing different Mce1Ns

from a plasmid grown in the same condition as in **c**. The uptake profile (*left*) shows accumulated

radioactivity counts in cells over time, and is representative of at least three independent experiments. Each

data point (mean ± standard deviation) represents results from three *technical* replicates. CPM, count per

minute. Uptake rates (*right*) are quantified based on [^{14}C]-palmitic acid levels after 30 min incubation. The

uptake of individual strains is normalized to that of WT cells harboring the empty vector (WT EV). Mean

± standard deviation of three *biological* replicates is shown for each group. Welch's t-test: NS, not

significant; * $p < 0.05$; ** $p < 0.01$. EV, empty vector (pMV306hsp); *0959*, *MSMEG_0959*.

Figure 5. Disulfide crosslinking validates the predicted YrbE1B-MSMEG-0959 model. a A zoomed-in view of contact sites between YrbE1B and MSMEG_0959 revealed by disulfide crosslinks and mapped onto the AlphaFold2 model. Positions on YrbE1B and MSMEG_0959 that allowed disulfide formation between the two proteins (see **b**) are highlighted in *magenta* and *green*, respectively. **b** α-FLAG (*left*) and α-His (*right*) immunoblot analyses showing crosslinking adducts formed, if any, between MSMEG_0959-FLAG and His$_6$-YrbE1B with cysteines incorporated at indicated sites, when the two proteins were expressed in *E. coli*. Wild type His$_6$-YrbE1B and MSMEG_0959-FLAG (Lane 1) serve as negative control. The samples were subjected to non-reducing or reducing SDS-PAGE before immunoblotting. A band putatively assigned as His$_6$-YrbE1B dimers is denoted with an asterisk.

Figure 6. A proposed model of Mce1 complexes and their regulation by Mce1N. Mce1 complexes are ABC transporters for fatty acids, with YrbE1A/B as TMDs, MceG as NBDs, and heterohexameric MCE-domain proteins as SBPs. There are two variants of Mce1 complexes in *M. smegmatis*, each containing MSMEG_6540 or Mce1A in addition to Mce1B–F. The relative order of protomers within heterohexameric SBP complexes is indicated based on the AlphaFold2 models (Supplementary Fig. 7b). Mce1N is a negative regulator of the Mce1 system; it specifically binds to YrbE1B and prevents its interaction with MceG.